BSX - Boston Scientific Corporation

Stock Details

Boston Scientific Corporation (BSX), a prominent company in the life sciences sector within the surgical & medical instruments & apparatus industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $106.15. Over the past 52 weeks, it has ranged between $71.88 and $108.94. This places the current price at 97.4% of its 52-week high and 47.7% above its 52-week low. Recent trading volume was recorded at 5,869,278. The International Securities Identification Number (ISIN) for this stock is US1011371077.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

77.76

Above market average

Forward P/E

36.63

Earnings expected to grow

PEG Ratio

2.62

Potentially overvalued

Price to Book

7.10

EV/EBITDA

41.25

EPS (TTM)

$1.37

Price to Sales

8.98

Beta

0.69

Less volatile than market

How is BSX valued relative to its earnings and growth?

Boston Scientific Corporation trades at a P/E ratio of 77.76, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 36.63 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 2.62 indicates a premium valuation even accounting for growth.

What is BSX's risk profile compared to the market?

With a beta of 0.69, Boston Scientific Corporation is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 7.10 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

11.60%

Operating Margin

20.10%

Return on Equity

9.50%

Return on Assets

5.28%

Revenue Growth (YoY)

20.90%

Earnings Growth (YoY)

36.40%

How profitable and efficient is BSX's business model?

Boston Scientific Corporation achieves a profit margin of 11.60%, meaning it retains $11.60 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 20.10% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 9.50% and ROA at 5.28%, the company achieves moderate returns on invested capital.

What are BSX's recent growth trends?

Boston Scientific Corporation's revenue grew by 20.90% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings increased by 36.40% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry averages for proper context.

Company Size & Market

Shares Outstanding

1.48B

Book Value/Share

$15.02

Asset Type

Common Stock

What is BSX's market capitalization and position?

Boston Scientific Corporation has a market capitalization of $157.61B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 1.48B shares outstanding, the company's ownership is widely distributed. As a major player in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry, it competes with other firms in this sector.

How does BSX's price compare to its book value?

Boston Scientific Corporation's book value per share is $15.02, while the current stock price is $106.15, resulting in a price-to-book (P/B) ratio of 7.07. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$117.55

10.74% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

How reliable are analyst predictions for BSX?

34 analysts cover BSX with 91% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $117.55 implies 10.7% upside, but targets are often adjusted to follow price moves rather than predict them.

What is the Wall Street consensus on BSX?

Current analyst recommendations:8 Strong Buy, 23 Buy, 3 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 03:10 AM

Boston Scientific Corporation (BSX) Stock